K Pharma (4896) · FactRestated
Progress in Developing the Legal Framework for Regenerative Medicine and Clinical Research
First written in FY2024-H1. 1 of 2 entries say "Restated". Latest entry: FY2024.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Progress in Developing the Legal Framework for Regenerative Medicine and Clinical ResearchA theme 1 companies write about · 0 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2024RestatedAnnual report
「The Act Partially Amending the Act on the Safety of Regenerative Medicine and the Clinical Trials Act was promulgated on 14 June 2024, amid steady progress in establishing the legal framework.」
The company reiterates progress in establishing the legal framework for regenerative medicine and clinical research as part of the business environment. - FY2024-H1First statedAnnual report
「The Act Partially Amending the Act on the Safety of Regenerative Medicine and the Clinical Trials Act was promulgated on 14 June 2024, amid steady progress in establishing the legal framework.」
The company first cites promulgation of the amended legislation on regenerative medicine safety and clinical research as a change in the business environment.